NCT02507167View on ClinicalTrials.gov

Impact of Two Genetic Variants of OATP1B3 or MRP2 or Rifampin on Systemic Disposition and Biological Efficacy of CCK-8

PHASE1CompletedINTERVENTIONAL
Enrollment

19

Participants

Timeline

Start Date

November 30, 2012

Primary Completion Date

July 31, 2013

Study Completion Date

December 31, 2014

Conditions
Gastrointestinal Hormones
Interventions
DIETARY_SUPPLEMENT

mixed meal

250 ml Fortimel compact (chocolate)

DRUG

Rifampin

oral rifampin administration (600 mg EREMFAT®)

Trial Locations (1)

17489

Department of Clinical Pharmacology, Greifswald

All Listed Sponsors
lead

University Medicine Greifswald

OTHER

NCT02507167 - Impact of Two Genetic Variants of OATP1B3 or MRP2 or Rifampin on Systemic Disposition and Biological Efficacy of CCK-8 | Biotech Hunter | Biotech Hunter